<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta http-equiv="X-UA-Compatible" content="ie=edge">
    <link rel="stylesheet" type="text/css" href="//fonts.googleapis.com/css?family=Open+Sans:400,300,600,700,800" />
    <link rel="stylesheet" href="index.bundle.css">
    <title>Ultragenyx Theme</title>
</head>
<body>

<div class="site">
    <div class="site__header">
        Menu
    </div>

    <div class="site__body">

        <div class="section section--disease">
            <div class="container">
                <div class="block block--hero">
                    <h1 class="block__title">Hereditary, progressive, and lifelong disease</h1>
                </div>
            </div>
        </div>

        <div class="section">
            <div class="container">
                <div class="block block--large">
                    <h1 class="block__title">What is XLH?</h1>
                    <p class="block__body">X-linked hypophosphatemia (XLH) is characterized by chronic hypophosphatemia due to increased fibroblast growth factor 23 (FGF23) activity.<sup>1,10</sup></p>
                </div>
                <div class="three-column">
                    <div class="three-column__1 icon">
                        <img src="/assets/images/global/hcp-rickets-osteomalacoia-icon.svg" alt="" class="icon__img">
                        <p class="icon__body">XLH leads to poor bone mineralization resulting in rickets and osteomalacia, the sources of progressive and compounding symptoms leading to skeletal defects, muscular dysfunction, and dental abnormalities.<sup>1-5</sup></p>
                    </div>
                    <div class="three-column__2 icon">
                        <img src="/assets/images/global/hcp-family-icon.svg" alt="" class="icon__img">
                        <p class="icon__body">XLH impacts the skeletal, muscular, and dental health of <a href="#" class="small-link">children</a> and <a href="#" class="small-link">adults</a> throughout their daily lives.<sup>6-8</sup></p>
                    </div>
                    <div class="three-column__3 icon">
                        <img src="/assets/images/global/hcp-family-tree-icon.svg" alt="" class="icon__img">
                        <p class="icon__body">XLH is inherited within families but about 20% to 30% of cases may arise spontaneously.<sup>9</sup> Ask about a patient’s family history for an <a href="#"class="small-link">accurate diagnosis</a>.
                    </div>
                </div>
            </div>
        </div>

        <div class="section section--turquoise">
            <div class="container">
                <div class="block text-center">
                    <h2 class="block__title color-white">Patients and healthcare providers may also know XLH as:</h2>
                </div>
                <div class="two-column two-column--list">
                    <div class="two-column__1">
                        <div class="two-column__body color-white">
                        <ul><li><span>X-linked hypophosphatemic rickets<sup>1,2</sup></span></li>
                        <li><span>Hereditary hypophosphatemic rickets<sup>3</sup></span></li>
                        <li><span>Familial hypophosphatemic rickets<sup>1</sup></span></li>
                        <li><span>Vitamin D–resistant rickets (VDRR)<sup>1</sup></span></li>
                        <li><span>Vitamin D–resistant osteomalacia<sup>4</sup></span></li>
                        <li><span>X-linked vitamin D–resistant rickets<sup>1</sup></span></li></ul>
                        </div>
                    </div>
                    <div class="two-column__2">
                        <div class="two-column__body color-white">
                        <ul><li><span>Hypophosphatemic rickets<sup>1</sup></span></li>
                        <li><span>Hypophosphatemic vitamin D–resistant rickets (HPDR)<sup>1</sup></span></li>
                        <li><span>X-linked rickets (XLR)<sup>1</sup></span></li>
                        <li><span>Genetic rickets<sup>5</sup></span></li>
                        <li><span>Familial hypophosphatemia<sup>5</sup></span></li></ul>
                        </div>
                    </div>
                </div>
            </div>
        </div>

        <div class="section section--grayish-white">
            <div class="container">
                <div class="block">
                    <h1 class="block__title">Increased FGF23 activity is the underlying cause of chronic hypophosphatemia<sup>13,14</sup></h1>
                    <p class="block__body">In normal homeostasis, FGF23 is a protein hormone mainly produced by osteocytes in the bones to regulate serum phosphate levels.<sup>10-12</sup></p>
                </div>
                <div class="three-column">
                    <div class="three-column__1 icon">
                        <img src="/assets/images/hcp/interior-1-1/desktop/bone.png" alt="" class="icon__img">
                        <p class="icon__body">In XLH, there is increased FGF23 activity, which leads to chronic hypophosphatemia<sup>11,13</sup></p>
                    </div>
                    <div class="three-column__2 icon">
                        <img src="/assets/images/hcp/interior-1-1/desktop/kidney.png" alt="" class="icon__img">
                        <p class="icon__body">Increased FGF23 activity decreases renal phosphate reabsorption, which increases urinary phosphate excretion and decreases calcitriol production<sup>11,13</sup>
                    </div>
                    <div class="three-column__3 icon">
                        <img src="/assets/images/hcp/interior-1-1/desktop/renal.png" alt="" class="icon__img">
                        <p class="icon__body">Decreased levels of calcitriol reduces intestinal phosphate absorption<sup>11,13</sup>
                    </div>
                </div>
            </div>
        </div>

        <div class="section">
            <div class="container">
                <div class="block">
                    <h1 class="block__title">Increased FGF23 activity impacts your patient</h1>
                    <p class="block__body">Increased FGF23 activity leads to chronic hypophosphatemia manifesting as rickets and osteomalacia, the sources of compounding symptoms in XLH.<sup>1,13-15</sup></p>
                </div>
                <div class="two-column">
                    <div class="two-column__1">
                        <div class="block">
                            <h3 class="block__title text-center">Pediatric patient</h3>
                        </div>
                        <img src="/assets/images/hcp/interior-1-1/desktop/graph02.png" alt="Consequence of XLH in children include delayed growth, pain, leg deformities, and decreased physical function" class="block__image">
                    </div>
                    <div class="two-column__2">
                        <div class="block">
                            <h3 class="block__title text-center">Adult patient</h3>
                        </div>
                        <img src="/assets/images/hcp/interior-1-1/desktop/graph01.png" alt="Consequence of XLH in adults include fractures, stiffness, pain, and decreased physical function" class="block__image">
                    </div>
                </div>
            </div>
        </div>

        <div class="section section--cta">
            <div class="container container--small">
                <div class="block text-center block--clear">
                    <h1 class="block__title color-white">Currently, there are no FDA-approved therapies to treat XLH.</h1>   
                    <p class="block__body color-white">Understanding the strategies to <a href="/hcp/disease-management/" class="link link--white">symptom management</a> in children and adults with XLH can help you provide better care for patients.</p>
                </div>
            </div>
        </div>

        <a href="/hcp/diagnostic-process/" class="link link--full">Understand how to diagnose XLH<img class="arrow arrow--right" src="/assets/images/global/arrow-hcp.svg"></a>
        
        <div class="section section--grayish-white">
            <div class="container">
                <div class="block block--reference">
                    <p class="block__title">References:</p>
                    <p class="block__body"><strong>1.</strong> Ruppe MD. X-linked hypophosphatemia. In: Pagon RA, Adam MP, Ardinger HH, et al, eds. <em>GeneReviews<sup>®</sup></em>. Seattle, WA; 1993. <strong>2.</strong> X-linked hypophosphatemia. Genetic and Rare Diseases Information Center (GARD) website. https://rarediseases.info.nih.gov/diseases/12943/x-linked-hypophosphatemia. Accessed September 26, 2017. <strong>3.</strong> Hereditary hypohosphatemic rickets. Genetics Home Reference website. https://ghr.nlm.nih.gov/condition/hereditary-hypophosphatemic-rickets. Accessed September 27, 2017. <strong>4.</strong> Wang M, Cao X, Cao B. Hypophosphatemic vitamin D-resistant osteomalacia: a case report. <em>Exp Ther Med</em>. 2013;6(3):791-795.<strong>5.</strong> What is XLH? XLH Network website. https://www.xlhnetwork.org/what-is-xlh/. Last modified August 13, 2017. Accessed September 27, 2017. <strong>6.</strong> Whyte MP, Schranck FW, Armamento-Villareal R. X-linked hypophosphatemia: a search for gender, race, anticipation, or parent of origin effects on disease expression in children. <em>J Clin Endocrinol Metab</em>. 1996;81(11):4075-4080. <strong>7.</strong> Linglart A, Dvorak-Ewell M, Marshall A, et al. Impaired mobility and pain significantly impact the quality of life of children with X-linked hypophosphatemia [abstract]. <em>Bone Abstracts</em>. 2015;4:P198. <strong>8.</strong> Skrinar A, Marshall A, Javier San Martin M, et al. X-linked hypophosphatemia (XLH) impairs skeletal health outcomes and physical function in affected adults. Paper presented at: Endocrine Society 97th Annual Meeting; March 5-8, 2015; San Diego, CA.<strong>9.</strong> Gaucher C, Walrant-Debray O, Nguyen TM, et al. PHEX analysis in 118 pedigrees reveals new genetic clues in hypophosphatemic rickets. <em>Hum Genet</em>. 2009;125(4):401-411. doi:10.1007/s00439-009-0631-z. <strong>10.</strong> Schiavi SC. Fibroblast growth factor 23: the making of a hormone. <em>Kidney Int</em>. 2006;69(3):425-427. <strong>11.</strong> Martin A, Quarles LD. Evidence for FGF23 involvement in a bone-kidney axis regulating bone mineralization and systemic phosphate and vitamin D homeostasis. <em>Adv Exp Med Biol</em>. 2012;728:65-83. <strong>12.</strong> Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. <em>J Clin Endocrinol Metab</em>. 2005;90(3):1519-1524. <strong>13.</strong> Carpenter TO, Imel EA, Holm IA, et al. A clinician’s guide to X-linked hypophosphatemia. <em>J Bone Miner Res</em>. 2011;26(7):1381-1388. <strong>14.</strong> Linglart A, Biosse-Duplan M, Briot K, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. <em>Endocr Connect</em>. 2014;3(1):R13-30. <strong>15.</strong> Data on file. Ultragenyx Pharmaceutical.</p>
                </div>
            </div>
        </div>


    </div>

    <div class="site__footer">
        Footer
    </div>
</div>

    <script src="index.bundle.js"></script>
</body>
</html>